Tasdemir, EyyupToptas, TayfurDemir, CengizEsen, RamazanAtmaca, Murat2025-05-102025-05-1020140300-97342000-196710.3109/03009734.2013.8615492-s2.0-84894072547https://doi.org/10.3109/03009734.2013.861549https://hdl.handle.net/20.500.14720/16378Demir, Cengiz/0000-0001-9856-184XBackground. Diabetic patients exhibit platelet hyperreactivity, which renders them resistant to antithrombotic treatments. We aimed to investigate the prevalence and predictors of aspirin resistance in diabetic patients. Material and methods. A total of 93 diabetic and 37 non-diabetic participants were included into the study. Aspirin resistance was measured with a whole-blood desktop platelet function analyzer (PFA-100) with an epinephrine agonist. Results. Altogether 41.9% patients with DM were aspirin non-responders. Aspirin resistance was observed in 43.2% of nondiabetic patients (p = 0.89). Presence of diabetes mellitus had no effect on aspirin response (RR 0.95 (95% CI 0.44-2.05), p = 0.89) in the whole study population. Hypercholesterolemia was the only predictor of aspirin resistance in multivariate analysis in diabetic patients (RR 3.09 (95% CI 1.17-8.16), p = 0.023). Conclusion. The prevalence of aspirin resistance is comparable in diabetic and non-diabetic patients. Hypercholesterolemia is the only independent predictor of aspirin resistance in diabetic patients.eninfo:eu-repo/semantics/openAccessAspirin ResistanceDiabetes MellitusPfa-100Article1191Q2Q1253124236750WOS:000331828500004